Molecular regulation of glial inflammation in Parkinson's disease
Parkinson's disease (PD) is the most prevalent movement disorder that affects adults, the primary pathology of which includes the loss of dopamine producing neurons from the substantia nigra (SN) and inflammatory activation of immune mediators in the brain. Reactive astrocytes and microglia have been implicated in driving the progressive phase of dopamine neuron loss in PD, the result of which leads to worsening neurodegeneration over time that no current therapy can inhibit. A significant need exists for small molecule therapeutics that reach the CNS, decrease glial activation, and confer ...
(For more, see "View full record.")